Citation

Gotthardt JD, Bello NT. Expert Rev Clin Pharmacol 2016; 9(10): 1289-1297.

Copyright

(Copyright © 2016, Informa Healthcare)

DOI

10.1080/17512433.2016.1232164

PMID

unavailable

Abstract

INTRODUCTION: Obesity is a major health concern for several countries. The United States (U.S.) has arguably led the world in the percentage of overweight and/or obese per capita for several decades. As a result, numerous FDA-approved pharmacotherapeutic options are available for the long-term treatment of obesity. Although most of these medications have been on the U.S. market for a few years and have demonstrated efficacy for long-term weight loss in clinical trials, the impact of these medications on obesity in the U.S. has yet to be realized. Areas covered: We will review and evaluate why pharmacotherapy for obesity has not produced a meaningful reduction in the number of overweight and obese adults in the U.S. Expert commentary: Several obstacles, such as adverse drug effects, poor insurance coverage, not treating obesity as a chronic disease, and availability of other weight loss alternatives, has resulted in poor performance of pharmacotherapy for obesity in the U.S. market. © 2016 Informa UK Limited, trading as Taylor & Francis Group.

Language: en

Keywords

United States; adult; human; suicide; insomnia; abdominal pain; suicidal ideation; suicidal behavior; kidney disease; obesity; migraine; fatigue; pancreatitis; vomiting; xerostomia; unclassified drug; headache; constipation; gastrointestinal symptom; dehydration; drug safety; placebo; patient compliance; drug efficacy; nausea; drug withdrawal; cardiovascular disease; fibromyalgia; lung edema; side effect; heart rate; liver toxicity; liver injury; low drug dose; non insulin dependent diabetes mellitus; dyspnea; surgical mortality; nausea and vomiting; dizziness; tobacco dependence; Article; tetrahydrolipstatin; bariatric surgery; sibutramine; pulmonary hypertension; valvular heart disease; drug dose comparison; lifestyle modification; recommended drug dose; antiobesity agent; steatorrhea; drug dose escalation; phentermine; low calory diet; upper abdominal pain; amfebutamone plus naltrexone; lorcaserin; phentermine plus topiramate; liraglutide; Orlistat; gastric banding; defecation urgency; fenfluramine plus phentermine; Belviq; Contrave; depressed blood pressure; dietary supplement; drug quality; gastric bypass surgery; heart murmur; naltrexone/bupropion; phentermine/topiramate; Qsymia; Saxenda